Literature DB >> 21544322

Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions.

P Kirchhof1, M Nabauer, A Gerth, T Limbourg, T Lewalter, A Goette, K Wegscheider, A Treszl, T Meinertz, M Oeff, U Ravens, G Breithardt, G Steinbeck.   

Abstract

Atrial fibrillation (AF) patients may receive treatment from specialists or from general medicine physicians representing different levels of care within a structured health care system. This "choice" is influenced by patient flow within a health care system, patient preference, and individual access to health care resources. We analysed how the postgraduate training and work environment of treating physicians affects management decisions in AF patients. Patient characteristics and treatment decisions were analysed at the time of enrolment into the registry of the German Atrial Fibrillation NETwork (AFNET). A total of 9,577 patients were enrolled from 2004 to 2006 in 191 German centres that belonged to the following four levels of care: 13 tertiary care centres (TCC) enrolled 3,795 patients (39.6%), 58 district hospitals (DH) enrolled 2,339 patients (24.4%), 62 office-based cardiologists (OC) enrolled 2,640 patients (27.6%), and 58 general practitioners or internists (GP) enrolled 803 patients (8.4%). Patients with new-onset AF were often treated in DH. TCC treated younger patients who more often presented with paroxysmal AF. Older patients and patients in permanent AF more often received outpatient care. Consistent with recommendations, younger patients and patients with non-permanent AF received rhythm control therapy more often. In addition, the type of centre affected the decision for rhythm control. Stroke risk was similar between centre types (mean CHADS2 scores 1.6 -1.9). TCC (68.8%) and OC (73.6%) administered adequate antithrombotic therapy more often than DH (55.1%) or GP (52.0%, p<0.001 between groups). Upon multivariate analysis, enrolment by TCC or OC was associated with a 1.60 (1.20-2.12, p=0.001) fold chance for adequate antithrombotic treatment. This difference between centre types was consistent irrespective of the type of stroke risk estimation (ESC 2001 guidelines, CHADS2 score), and also consistent when the recently suggested CHA2DS2-VASc score was used to estimate stroke risk. In conclusion, management decisions in AF are influenced by the education and clinical background of treating physicians in Germany. Inpatients receive more rhythm control therapy. Adequate antithrombotic therapy is more often administered in specialist (cardiologist) centres.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544322     DOI: 10.1160/TH11-02-0070

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

Review 1.  Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference.

Authors:  Paulus Kirchhof; Gregory Y H Lip; Isabelle C Van Gelder; Jeroen Bax; Elaine Hylek; Stefan Kaab; Ulrich Schotten; Karl Wegscheider; Giuseppe Boriani; Axel Brandes; Michael Ezekowitz; Hans Diener; Laurent Haegeli; Hein Heidbuchel; Deirdre Lane; Luis Mont; Stephan Willems; Paul Dorian; Maria Aunes-Jansson; Carina Blomstrom-Lundqvist; Maria Borentain; Stefanie Breitenstein; Martina Brueckmann; Nilo Cater; Andreas Clemens; Dobromir Dobrev; Sergio Dubner; Nils G Edvardsson; Leif Friberg; Andreas Goette; Michele Gulizia; Robert Hatala; Jenny Horwood; Lukas Szumowski; Lukas Kappenberger; Josef Kautzner; Angelika Leute; Trudie Lobban; Ralf Meyer; Jay Millerhagen; John Morgan; Felix Muenzel; Michael Nabauer; Christoph Baertels; Michael Oeff; Dieter Paar; Juergen Polifka; Ursula Ravens; Ludger Rosin; W Stegink; Gerhard Steinbeck; Panos Vardas; Alphons Vincent; Maureen Walter; Günter Breithardt; A John Camm
Journal:  Europace       Date:  2011-07-26       Impact factor: 5.214

2.  Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: a Danish survey.

Authors:  Axel Brandes; Mikkel Overgaard; Liane Plauborg; Christian Dehlendorff; Frede Lyck; Jørgen Peulicke; Søren Vinther Poulsen; Steen Husted
Journal:  Clin Cardiol       Date:  2013-05-13       Impact factor: 2.882

3.  Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use.

Authors:  Thomas Wilke; Antje Groth; Matthias Pfannkuche; Oliver Harks; Andreas Fuchs; Ulf Maywald; Bernd Krabbe
Journal:  J Thromb Thrombolysis       Date:  2015-07       Impact factor: 2.300

Review 4.  Stroke And Bleeding Risk Assessment: Where Are We Now?

Authors:  Mikhail S Dzeshka; Gregory Y H Lip
Journal:  J Atr Fibrillation       Date:  2014-04-30

5.  Primary Care Atrial Fibrillation Service: outcomes from consultant-led anticoagulation assessment clinics in the primary care setting in the UK.

Authors:  Moloy Das; Lee Panter; Gareth J Wynn; Rob M Taylor; Neil Connor; Joseph D Mills; Paulus Kirchhof; Dhiraj Gupta
Journal:  BMJ Open       Date:  2015-12-09       Impact factor: 2.692

6.  Stroke prevention in atrial fibrillation and 'real world' adherence to guidelines in the Balkan Region: The BALKAN-AF Survey.

Authors:  Tatjana S Potpara; Gheorghe-Andrei Dan; Elina Trendafilova; Artan Goda; Zumreta Kusljugic; Sime Manola; Ljilja Music; Rodica Musetescu; Elisabeta Badila; Gorana Mitic; Vilma Paparisto; Elena S Dimitrova; Marija M Polovina; Stanislav L Petranov; Hortensia Djergo; Daniela Loncar; Amira Bijedic; Sandro Brusich; Gregory Y H Lip
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

7.  Computational mapping identifies localized mechanisms for ablation of atrial fibrillation.

Authors:  Sanjiv M Narayan; David E Krummen; Michael W Enyeart; Wouter-Jan Rappel
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

8.  Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany - results from the German AFNET registry.

Authors:  Karl Georg Haeusler; Andrea Gerth; Tobias Limbourg; Ulrich Tebbe; Michael Oeff; Karl Wegscheider; András Treszl; Ursula Ravens; Thomas Meinertz; Paulus Kirchhof; Günter Breithardt; Gerhard Steinbeck; Michael Nabauer
Journal:  BMC Neurol       Date:  2015-08-05       Impact factor: 2.474

9.  Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF).

Authors:  Paulus Kirchhof; Bettina Ammentorp; Harald Darius; Raffaele De Caterina; Jean-Yves Le Heuzey; Richard John Schilling; Josef Schmitt; Jose Luis Zamorano
Journal:  Europace       Date:  2013-10-01       Impact factor: 5.214

Review 10.  Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis.

Authors:  Fernando J Vazquez; Joaquín P Gonzalez; Esteban Gándara
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.